Currently out of the existing stock ratings of Yanan Zhu, 91 are a BUY (77.12%), 27 are a HOLD (22.88%).

Yanan Zhu

Work Performance Price Targets & Ratings Chart

Analyst Yanan Zhu, currently employed at WELLS FARGO, carries an average stock price target met ratio of 44.44% that have a potential upside of 55.44% achieved within 96 days.

Yanan Zhu’s has documented 234 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SYRE, Spyre Therapeutics at 20-Feb-2026.

Wall Street Analyst Yanan Zhu

Analyst best performing recommendations are on RGLS (REGULUS THERAPEUTICS).
The best stock recommendation documented was for RGLS (REGULUS THERAPEUTICS) at 3/27/2025. The price target of $6 was fulfilled within 34 days with a profit of $4.5 (300%) receiving and performance score of 88.24.

Average potential price target upside

of $84.46 (21.84%) on ARGX (ARGENX NV ADR).
of $39.9 (98.82%) on IONS (IONIS PHARMACEUTICALS).
of $32.66 (24.14%) on BLUE (BLUEBIRD BIO).

ARGX argenx NV ADR EDIT Editas Medicine RAPT RAPT Therapeutics AVRO AVROBIO BLUE Bluebird bio SGMO Sangamo Therapeutics AGLE Aeglea Bio Therapeutics AGTC Applied Genetic TSHA Taysha Gene Therapies BEAM Beam Therapeutics NTLA Intellia Therapeutics AFMD Affimed NV AUTL Autolus Therapeutics Ltd FATE Fate Therapeutics IOVA Iovance Biotherapeutics RNA Avidity Biosciences GRCL Gracell Biotechnologies TCRT Alaunos Therapeutics IONS Ionis Pharmaceuticals SYRE Spyre Therapeutics ARCT Arcturus Therapeutics Holdings CCXI ChemoCentryx MNTA Momenta Pharmaceuticals QURE Uniqure NV RGLS Regulus Therapeutics SRPT Sarepta Therapeutics VYGR Voyager Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Derek Archila (WELLS FARGO)